To screen Bacillus clausii UBBC07 as a putative probiotic strain and to examine the protective effect of probiotic—B. clausii UBBC07 spore on uremia on rats induced by acetaminophen. In vitro tests performed to screen potential probiotic strains were gastric and bile acid resistance and ability to reduce pathogen adhesion to surfaces. An in vivo study was performed on rats (n = 18) which were randomly divided into three groups: group I, control—receives normal food and water, groups II and III receive acetaminophen i.p. at the dose of 550 mg/kg/day for 10 days, groups III was treated with B. clausii UBBC07 at a dose of 1 × 10⁹ CFU/day for 15 days. Urea, creatinine, malondialdehyde (MDA), and GSH levels and antioxidant enzymes like super oxide dismutase (SOD) and catalase activity were considered to analyze renal failure. Plasma urea and creatinine levels (p < 0.05) significantly increase and SOD, catalase, and GSH activity level significantly decrease in group II as compared with the control group. After treatment with probiotic, there was a significant increase in SOD and catalase (p < 0.05) and a significant decrease in serum urea, creatinine, and MDA (p < 0.05) in group III in response to group II. The results also revealed that probiotic was able to tolerate pH 3.0–9.0 and 0.3% bile salt. The present study suggests that B. clausii UBBC07 could be used as a novel alternative natural therapy for uremia, a major syndrome of CKD.

中文翻译：

---

形成孢子的益生菌克劳氏芽孢杆菌UBBC07对乙酰氨基酚诱发的大鼠尿毒症的治疗前景。

到屏幕克劳氏芽孢杆菌UBBC07为推定益生菌菌株，并审查probiotic-的保护作用克劳氏芽孢杆菌UBBC07孢子上尿毒症对乙酰氨基酚诱导的大鼠。筛选潜在益生菌菌株的体外测试是胃酸和胆汁酸抵抗力以及减少病原体与表面粘附的能力。对大鼠（n  = 18）进行了一项体内研究，将其随机分为三组：第一组，对照组-接受正常食物和水，第二组和第三组以550 mg / kg /天的剂量接受对乙酰氨基酚ip 10天时，III组用克劳氏芽孢杆菌UBBC07治疗，剂量为1×10 ⁹ CFU /天，共15天。尿素，肌酐，丙二醛（MDA）和GSH水平以及抗氧化酶（如超氧化物歧化酶（SOD）和过氧化氢酶活性）被认为可以分析肾衰竭。 与对照组相比，II组的血浆尿素和肌酐水平显着增加（p <0.05），SOD，过氧化氢酶和GSH活性水平显着下降。益生菌治疗后， 对第二组的反应，第三组的SOD和过氧化氢酶显着增加（p  <0.05），血清尿素，肌酐和MDA显着降低（p <0.05）。结果还表明，益生菌能够耐受pH 3.0-9.0和0.3％的胆汁盐。本研究表明克劳氏芽孢杆菌 UBBC07可用作尿毒症（一种CKD的主要综合征）的新型替代性自然疗法。